JP2024540480A5 - - Google Patents

Info

Publication number
JP2024540480A5
JP2024540480A5 JP2024529330A JP2024529330A JP2024540480A5 JP 2024540480 A5 JP2024540480 A5 JP 2024540480A5 JP 2024529330 A JP2024529330 A JP 2024529330A JP 2024529330 A JP2024529330 A JP 2024529330A JP 2024540480 A5 JP2024540480 A5 JP 2024540480A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
seq
kidney disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540480A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079987 external-priority patent/WO2023091968A1/en
Publication of JP2024540480A publication Critical patent/JP2024540480A/ja
Publication of JP2024540480A5 publication Critical patent/JP2024540480A5/ja
Pending legal-status Critical Current

Links

JP2024529330A 2021-11-17 2022-11-16 腎臓疾患の貧血を処置する方法 Pending JP2024540480A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163280594P 2021-11-17 2021-11-17
US63/280,594 2021-11-17
US202263419648P 2022-10-26 2022-10-26
US63/419,648 2022-10-26
PCT/US2022/079987 WO2023091968A1 (en) 2021-11-17 2022-11-16 Methods for treating anemia of kidney disease

Publications (2)

Publication Number Publication Date
JP2024540480A JP2024540480A (ja) 2024-10-31
JP2024540480A5 true JP2024540480A5 (https=) 2025-11-21

Family

ID=84923162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529330A Pending JP2024540480A (ja) 2021-11-17 2022-11-16 腎臓疾患の貧血を処置する方法

Country Status (8)

Country Link
US (1) US20240417458A1 (https=)
EP (1) EP4433160A1 (https=)
JP (1) JP2024540480A (https=)
KR (1) KR20240101681A9 (https=)
AU (1) AU2022394462A1 (https=)
CA (1) CA3235096A1 (https=)
MX (1) MX2024006006A (https=)
WO (1) WO2023091968A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204283A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
AU2004231122B2 (en) 2003-04-15 2010-04-08 Xenon Pharmaceuticals Inc. Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CA2549477A1 (en) 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP2723861A4 (en) 2011-06-21 2014-12-10 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
RU2014121043A (ru) 2011-10-24 2015-12-10 Эббви Инк. Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
CA2855570A1 (en) * 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CA3204283A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
EP3139957A4 (en) 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
GB201507926D0 (en) 2015-05-08 2015-06-24 Proqr Therapeutics N V Improved treatments using oligonucleotides
CA2991637C (en) 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
CA3029890A1 (en) 2016-07-07 2018-01-11 Acceleron Pharma Inc. Tgf-beta superfamily heteromultimers and uses thereof
CN113164766B (zh) * 2018-10-23 2025-02-25 供石公司 RGMc选择性抑制剂及其用途
AU2021273014A1 (en) * 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease

Similar Documents

Publication Publication Date Title
US20150197574A1 (en) Use of transferrin receptor antagonist for the treatment of thalassemia
JP2024540480A5 (https=)
WO2017064615A1 (en) Use of c5 inhibitors in transplant associated microangiopathy
JP2021113190A5 (https=)
CA3087699A1 (en) Methods for treating il-6 mediated inflammation without immunosuppression
JP7240177B2 (ja) 方法、レジメン、組み合わせ、及びアンタゴニスト
JP2023533030A5 (https=)
JP2023533682A5 (https=)
IE61008B1 (en) Composition for increasing the hematocrit of a normal mammal
EP4615867A1 (en) Methods for the treatment of cardiovascular disease
AU2020387399A1 (en) Methods of treating warm autoimmune hemolytic anemia using anti-FcRn antibodies
PT1737490E (pt) Processos de tratamento da aterosclerose
JP2023539047A5 (https=)
Locatelli et al. Resistance to erythropoiesis stimulating agent (ESA) treatment
US20250353905A1 (en) Compositions and methods for treating postural tachycardia syndrome
CN115814076A (zh) 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
KR20220036371A (ko) 항-lag-3 항체를 포함하는 제제, 이의 제조방법 및 용도
TWI886758B (zh) 抗pvrig/抗tigit雙特異性抗體在治療惡性腫瘤中的用途
CN119095618B (zh) 用于治疗巨噬细胞活化综合征的组合物和方法
WO2025223394A1 (en) Combination therapy for classic hodgkin's lymphoma
WO2006084145A2 (en) Methods of using il-1 antagonists to reduce c-reactive protein
US20210017278A1 (en) Treatment and Prophylaxis of Amyloidosis
WO2025157167A1 (zh) 靶向Nectin-4的抗体药物缀合物的用途
RU2021125057A (ru) ДОЗЫ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ АТИПИЧНОГО ГЕМОЛИТИКО-УРЕМИЧЕСКОГО СИНДРОМА (аГУС)
CN119300863A (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途